Neurokinin-1 Receptor Antagonists CP-96,345 and L-733,060 Protect Mice from Cytokine-Mediated Liver Injury

RENATE BANG, GABRIELE SASS, ALEXANDRA K. KIEMER, ANGELIKA M. VOLLMAR, WINFRIED L. NEUHUBER, and GISA TIEGS

Institute of Experimental and Clinical Pharmacology and Toxicology (R.B., G.S., G.T.) and Institute of Anatomy I (W.L.N.), University of Erlangen-Nuremberg, Erlangen, Germany; and Department of Pharmacy (A.K.K., A.M.V.), Centre of Drug Research, Pharmaceutical Biology, University of München, München, Germany

Received August 27, 2002; accepted December 19, 2002

ABSTRACT
Previously, we have shown that primary afferent sensory neurons are necessary for disease activity in T cell-mediated immune hepatitis in mice. In the present study, we analyzed the possible role of substance P (SP), an important proinflammatory neuropeptide of these nerve fibers, in an in vivo mouse model of liver inflammation. Liver injury was induced by bacterial lipopolysaccharide (LPS) in D-galactosamine (GalN)-sensitized mice. Depletion of primary afferent nerve fibers by neonatal capsaicin treatment down-regulated circulating levels of the proinflammatory cytokines tumor necrosis factor-α (TNFα) and interferon-γ (IFNγ) and protected mice from GalN/LPS-induced liver injury. Likewise, pretreatment of mice with antagonists of the SP-specific neurokinin-1 receptor (NK-1R), i.e., (2S)-cis-2-(diphenylmethyli)-N-(2-methoxyphenyl)-methyl-1-azabicyclo(2.2.2)-octan-3-amine (CP-96,345) and (2S,3S)-cis-3-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-phenylpiperidine (L-733,060), dose dependently protected mice from GalN/LPS-induced liver injury. The presence of the NK-1R in the murine liver was demonstrated by reverse transcription-polymerase chain reaction, sequence analysis, and immunocytochemistry. NK-1R blockade reduced inflammatory liver damage, i.e., edema formation, neutrophil infiltration, hepatocyte apoptosis, and necrosis. To get further insight into the mechanism by which receptor blockade attenuated GalN/LPS-induced liver damage, we analyzed plasma levels and intrahepatic expression of TNFα, IFNγ, interleukin (IL)-6, and IL-10. NK-1R blockade clearly inhibited GalN/LPS-induced production of TNFα and IFNγ, whereas synthesis of the hepatoprotective cytokines IL-6 and IL-10 was increased. NK-1 receptor antagonists might be potential drugs for treatment of inflammatory liver disease, most likely by inhibiting SP effects.

Capsaicin-sensitive primary afferent neurons, mainly equipped with unmyelinated C-fibers, are responsible for neurogenic inflammation in peripheral organs such as respiratory and gastrointestinal tract and skin (Holzer, 1988). The proinflammatory effects are most likely mediated by local effector functions of these neurons, i.e., by local release of several neuropeptides such as tachykinins and calcitonin gene-related peptide from their nerve terminals during peripheral inflammation (Holzer, 1988). Nevertheless, these nerve fibers also transmit afferent signals to the spinal cord in response to pain and inflammation (Holzer, 1988). The tachykinin substance P (SP) is considered a serious candidate mediator of neurogenic inflammation, although it is probably not the only one (Harrison and Geppetti, 2001). Hallmarks of neurogenic inflammation are increase in vascular permeability, plasma extravasation, edema formation, and leukocyte infiltration (Holzer, 1988; Harrison and Geppetti, 2001). In vitro, SP elicits activation of the proinflammatory transcription factor NF-κB (Marriott et al., 2000) and activates immune cells to produce cytokines (Lotz et al., 1988; Rameshwar et al., 1994). SP preferentially binds to the G protein-coupled neurokinin-1 receptor (NK-1R; Harrison and Geppetti, 2001). Studies using either NK-1R antagonists or mice genetically deficient in the NK-1R have proven a role for this receptor in asthma and chronic bronchitis, intestinal inflammation, pancreatitis, and resistance to infection (Kincy-Cain and Bost, 1996; Harrison and Geppetti, 2001).

Until now, only limited data are available regarding the role of primary afferent neurons in the liver under both

This work was supported by the Deutsche Forschungsgemeinschaft (DFG) Grant NE 534/1-1.

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

DOI: 10.1124/jpet.102.043539.

ABBREVIATIONS: SP, substance P; NF-κB, nuclear factor-κB; NK-1R, neurokinin-1 receptor; LPS, lipopolysaccharide; GalN, D-galactosamine; TNFα, tumor necrosis factor-α; IFNγ, interferon-γ; IL, interleukin; CP-96,345, (2S,3S)-cis-2-(diphenylmethyli)-N-(2-methoxyphenyl)-methyl-1-azabicyclo(2.2.2)-octan-3-amine; L-733,060, (2S,3S)-cis-3-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-phenylpiperidine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NPC, nonparenchymal liver cells; RT-PCR, reverse transcription-polymerase chain reaction; bp, base pair; DTT, dithiothreitol; AP-1, activator protein-1; TBS, Tris-buffered saline; SR 140333, nolpitantium.
physiological and pathophysiological conditions. These nerve fibers are detectable by SP and calcitonin gene-related peptide immunoreactivity in the portal tract of human (Stoyanov and Gulubova, 1998) and rodent (Markus et al., 1998; Tiets et al., 1999) livers. Immunoreactive nerve fibers were capsaicin-sensitive, i.e., they were completely absent in adult mice that have been treated with capsaicin three days after birth to permanently deplete the C-fibers (Tiets et al., 1999). Evidence for a functional role of these capsaicin-sensitive nerve fibers in liver injury has been demonstrated in experimental liver fibrosis induced by common bile duct ligation (Casini et al., 1990). We have shown recently that these nerve fibers are absolutely required for disease activity in T cell-mediated immune hepatitis in mice (Tiets et al., 1999).

In the present study, we analyzed the possible role of NK-1R, the principal SP binding receptor (Harrison and Gepetti, 2001), in an in vivo model of severe inflammatory liver injury inducible by bacterial lipopolysaccharides (LPS) in d-galactosamine (GalN)-sensitized mice. In this model, LPS induces the release of a variety of cytokines including tumor necrosis factor-α (TNFα), interferon-γ (IFNγ), and interleukin (IL)-6 and IL-10. TNFα (reviewed in Schümann and Tiets, 1999) and IFNγ (Car et al., 1994) are detrimental mediators of GalN/LPS-induced liver failure and lethality, whereas IL-6 and IL-10 are hepatoprotective (Mizuhashi et al., 1994; Louis et al., 1997; Galun et al., 2000), and IL-6 is critical for liver regeneration (Streetz et al., 2000). We pre-treated mice with antagonists of the NK-1R, i.e., CP-96,345 (Snyder et al., 1991) and L-733,060 (Rupniak et al., 1996) and analyzed their hepatoprotective and anti-inflammatory potential in GalN/LPS-induced liver damage. Since high-affinity binding sites have not yet been detected in the normal rodent liver (Hershey and Krause, 1990; Tauchida et al., 1990), we analyzed NK-1R mRNA expression in livers of mice and compared it with NK-1R mRNA expression in lung and spinal cord. Moreover, because NK-1R expression has been detected on monocytes (Ho et al., 1997), macrophages, and dendritic cells (Ho et al., 1997; Marriot and Bost, 2000, 2001) and since macrophages are the prime inflammatory cells activated by LPS, we analyzed NK-1R mRNA expression in nonparenchymal liver cells, which are enriched in Kupffer cells. We also investigated the cellular distribution of NK-1R specific immunofluorescence in mouse liver sections.

Materials and Methods

Animals. BALB/c mice (age, 6–8 weeks; weight range, 18–22 g) were obtained from the animal facilities of the Institute of Experimental and Clinical Pharmacology and Toxicology of the University of Erlangen-Nuremberg (Erlangen, Germany). All mice received humane care according to the guidelines of the National Institutes of Health (Bethesda, MD) and to the legal requirements in Germany. They were maintained under controlled conditions (22°C, 55% humidity, and 12-h day/night rhythm) and fed a standard laboratory chow.

Doses and Application Routes. For capsaicin pretreatment, newborn BALB/c mice were injected with 100 mg/kg capsaicin subcutaneously (s.c.) in a volume of 40 μl on the 3rd day after birth. Capsaicin (Sigma/RBI, Natick, MA) was initially dissolved in 100% ethanol and further diluted with sterile phosphate-buffered saline and Tween 80 to a final concentration of 5 mg/ml in 10% Tween and 10% ethanol. Control animals received the solvent without capsaicin. Seven weeks after injection, the effectiveness of the capsaicin treatment was assessed by the eye-wiping test; a trop of a 0.1 mg/ml solution of capsaicin in saline was applied into one eye with a plastic Pasteur pipette. All control animals wiped the eye rigorously (>30 s with a latency of >5 s) while treated animals showed a latency of >5 s to the first wipe and did not carry out more than 5 wipes. Most treated animals did not respond at all.

All other reagents were injected in a total volume of 250 μl/25 g of mouse. LPS from Salmonella abortus equi, was purchased from Metalon (Ragow, Germany) and administered intraperitoneally at a concentration of 6.5 μg/kg together with 700 mg/kg GalN (Roth GmbH, Karlsruhe, Germany) in pyrogen-free saline in the same solution.

The NK-1R antagonists CP-96,345 (a generous gift from Dr. H. Berghof; Pfizer GmbH, Karlsruhe, Germany) or L-733,060 (Tocris/Biotrend Chemikalien GmbH, Köln, Germany) were administered in doses of 1.25 to 20 mg/kg i.p. 30 min before GalN/LPS challenge.

Analysis of Liver Enzymes. Hepatocyte damage was assessed 8 h after GalN/LPS administration by measuring plasma enzyme activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using an automated procedure (Bergmeyer, 1984).

Isolation of Nonparenchymal Liver Cells. Nonparenchymal liver cells (NPC) of untreated mice or mice that have been treated for either 3 or 6 h with 6.5 μg/kg Salmonella abortus equi LPS were prepared as described previously (Gantner et al., 1996). Briefly, after collagenase digest, supernatants from two consecutive 100g centrifugations of liver cells were pooled and centrifuged for 8 min at 400 g. The pellet containing the NPC fraction was washed twice and stored at −80°C until preparation of RNA. The NPC fraction contained about 50% Kupffer cells and less than 0.5% hepatocytes. The proportion of Kupffer cells in the NPC fraction was determined using cytospin slides stained with the rat anti-macrophage antibody BM8 (Dianova, Hamburg, Germany) and a secondary rabbit anti-rat FITC labeled antibody (DAKO, Hamburg, Germany). Hepatocytes were identified according to their morphology.

Cytokine Determination by Enzyme-Linked Immunosorbent Assay. Sandwich enzyme-linked immunosorbent assays for murine plasma TNFα, IFNγ, IL-6, and IL-10 were performed using flat-bottom high-binding polystyrene microtiter plates (Greiner GmbH, Frickenhausen, Germany). Antibodies were purchased from BD Biosciences (Heidelberg, Germany). Streptavidin-peroxidase (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) and the peroxidase chromogen tetramethylbenzidine (Boehringer Mannheim, Mannheim, Germany) were used according to the manufacturer’s recommendations. Plasma cytokines. Plasma cytokines levels were assessed after the hepatotoxic challenge at the time points indicated or at the time points of their maximal release (Fig. 3B), i.e., TNFα, IL-6, and IL-10 1 h after GalN/LPS administration and IFNγ 8 h after GalN/LPS administration.

Determination of Cytokine and NK-1 Receptor mRNA by RT-PCR and Real-Time RT-PCR. Total RNA was isolated from liver tissue, NPC, lung, or spinal cord of untreated mice or at the indicated time points after LPS administration, using the Nucleo Spin RNA purification kit (BD Biosciences Clontech, Palo Alto, CA). To analyze altered gene expression, mRNA from 1 μg of total RNA was transcribed into cDNA using SuperScript II RNase H reverse transcriptase (Invitrogen, Carlsbad, CA). Oligonucleotides and Taq polymerase for subsequent PCR reactions were also obtained from Invitrogen (Carlsbad, CA)

Primers were selected for murine TNFα, IL-6, IL-10, IFNγ, NK-1R, and β-actin (Invitrogen): TNFα: 5′-AGT AGC AGA AGC ATG ATC (158–178) and 3′-GTC TGG GCC ATA GAA C (386–371 in GenBank accession no. X02611); IL-6 and IL-10: 5′-GTT ACT TGG GTT CTG GCC AAC (91–115) and 3′-GAA CGC TAC CCC GGT CCC TGC (663–683 in GenBank accession no. J03783); IL-10: 5′-GTT ACT TGG GTT GCC AAC (91–115) and 3′-GGA GTG TAC ATG TAT GCT TC (294–318 in GenBank accession no. J03783); IFNγ: 5′-GAA CCG TAC ACA CAT CTT TGC CTC TCT (113–131) and 3′-GAG GTC ATT GAA TGC TGT G (513–494 in GenBank accession no. M28621); NK-1Rout: 5′-GCT

Downloaded from jpet.aspetjournals.org at ASPET Journals on November 19, 2017
TCA AGC ATG CCT TGC G (964–982) and 3′-GCC AGA ATG TTA GAG TAG AAG (1240–1260 in GenBank accession no. X02934); NK-1nest: 5′-GAT ACC TCC AGA CCC AGA G (1039–1055) and 3′-GCT GGA GCT TCT TGT CAT G (1220–1202 in GenBank accession no. X02934); β-actin: 5′-TTG AAT CCT GTG GCA TCC ATG AAA (729–752) and 3′-TAA AAC GCA GCT CAG TAA CAG TCC G (1076–1053 in GenBank accession no. X03765). For quantitative evaluation of cytokine and β-actin mRNA expression, real-time RTPCRs of at least six livers of mice for each time point and treatment were used. For each liver, β-actin expression, defined by its crossing point, was measured to verify equal amounts of cDNA. Using a Light Cycler system (Roche Molecular Biochemicals, Mannheim, Germany) a crossing point is defined as the third cycle in the exponential phase of amplification, which is specific for each sample. Crossing points of TNFα, IL-6, and IL-10 were measured in the same way using the specific primers. Quantification of expression levels was done by calculating the difference of β-actin and the regulated PCRs crossing points giving distances of cycles, 1 cycle difference being equivalent to a 2-fold induction. Finally, expression of untreated samples was defined as 1-fold, and the induction levels of all treated samples were related to that. The NK-1R PCR from liver and NPC cDNA was performed as nested-PCR with primary RT-PCR amplifications (15 cycles with the NK-1R out primer pair), which amplified a 276-bp fragment of the NK-1R sequence. For the second (nested) RT-PCR reaction, the 276-bp fragment was used as template for amplification with the NK-1Rnest primer pair in the light cycle system. NK-1R mRNA expression in lung and spinal cord was measured in the light cycle system without previous amplification by RT-PCR. To demonstrate the length of the individual fragments, light cycle PCR products were analyzed by agarose gel electrophoresis. To confirm amplification specificity, PCR products were subjected to a melting curve analysis, and in the case of NK-1R, the PCR products were sequenced.

**Cloning and DNA Sequencing.** PCR synthesized DNA was extracted by concert gel extraction systems (Invitrogen, Karlsruhe, Germany) and cloned into a plasmid vector by the TOPO TA cloning method (Invitrogen). After transformation, Escherichia coli recombinants were selected for ampicillin resistance. The DNA sequence was determined using the Promega labeling kit according to manufacturer’s instructions (Madison, WI). For DNA binding reaction, 5 μg of nuclear protein were incubated for 20 min at RT in a 15-μl reaction volume containing 10 mM Tris-HCl, pH 7.5, 50,000 cpm of radio-labeled oligonucleotide probe, 2 μg of synthetic carrier copolymers (poly dl-dC), 4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 50 mM NaCl, and 0.5 mM DTT. Oligonucleotide complexes were resolved by electrophoresis (4.5% nondenaturing polyacrylamide gel, 100 V). Signals were detected by phosphoimaging. The specificity of the DNA-protein complex was confirmed by competition with a 100-fold excess of unlabeled NF-κB, AP-1, and AP-2 (5′-GAT CGA ACT GAC CGC CCG CGG CCC GT-3′) binding sequences, respectively.

**Immunocytochemistry.** Livers were excised from euthanized mice and immersion fixed in phosphate buffered formaldehyde for 4 to 6 h. After cryoprotection in 15% buffered sucrose, 12-μm cryostat sections were mounted on poly-L-lysine-coated slides, preincubated in TBS containing 1% bovine serum albumin, 0.5% Triton X-100, 0.05% thimerosal, and 5% goat normal serum for 1h at room temperature and incubated with rabbit anti-NK-1R (Chemicon, Hofheim, Germany) diluted 1:500 in TBS containing 1% bovine serum albumin, 0.5% Triton X-100, and 0.05% thimerosal for 48 h at 4°C. After three rinses in TBS, binding sites of antibodies were revealed using goat anti-rabbit IgG tagged with Alexa 488 (Molecular Probes, MobiTec GmbH, Göttingen, Germany) diluted 1:1000 in TBS with the same additives as for the primary antibody. After another 3 rinses in TBS, sections were coveredslipped in TBS-glycerol 1:1, pH 8.6. As a positive control, sections from mouse brain and spinal cord were processed in parallel. Negative controls included replacement of the primary antibody by rabbit normal serum or TBS.

**Confoocal Laser Scanning Microscopy.** Confocal single optical sections at a resolution of about 500 nm were taken on a Biorad MRC 1000 scanning system (Biorad, Hemel Hempstead, UK) equipped with an argon-krypton laser (American Laser Corporation, Salt Lake City, UT) attached to a Nikon Diaphot 300. A 60× oil immersion lens was used. The Alexa 488 signal was recorded in one channel while a second channel was used to detect background fluorescence of the tissue elicited by the 568-nm line of the laser. Merged images were formatted as .TIF files and adjusted for contrast and brightness using Adobe Photoshop 6.0.

**Histology.** Formalin-fixed liver tissue was embedded in paraffin and 4-μm thick sections were randomly taken throughout the whole organ and stained with H&E using a standard protocol. In each section, three randomly selected areas measuring 86,400 μm² each were screened for edema, granulocytes, and hepatocyte apoptosis and necrosis.

**Statistical Analysis.** The results were analyzed using Student’s t test if two groups were compared or by analysis of variance followed by the Dunnett’s test if more groups were tested against a control group. If variances were inhomogeneous in the Student’s t test, the results were analyzed using the Welsh test. All data in this study are expressed as a mean ± S.E.M. P values less than or equal to 0.05 were considered significant.

**Results**

**Role of Capsaicin-Sensitive Primary Afferent Neurons for Liver Injury and Cytokine Production.** We have described previously that permanent depletion of primary sensory neurons by neonatal capsaicin treatment prevented immune-mediated liver injury in mice elicited by activation of T cells (Tregs et al., 1999). To prove whether these nerve fibers are also critical for liver damage and cytokine production in the macrophage-dependent GalN/LPS model (Freudenberg et al., 1986), we treated 7- to 8-week-old mice, which had received either capsaicin or solvent (see Materials and Methods) 3 days after birth, with GalN and LPS. As shown in Fig. 1A, capsaicin-pretreated mice were protected from liver damage, as assessed by significantly reduced lev-
els of the plasma transaminases ALT and AST 8 h after the concomitant administration of GalN and LPS. The protective capsaicin effect was accompanied by dramatically reduced circulating maximal levels of the proinflammatory mediators TNFα and IFNγ at 1 and 8 h, respectively (Fig. 1B; for cytokine maximum levels, see Fig. 4B).

**Dose Dependence of the Protective Effect of NK-1 Receptor Antagonists against GalN/LPS-Induced Liver Injury.** Since SP is the most prominent proinflammatory neuropeptide of primary afferent neurons, we investigated the pharmacological effects of antagonists directed against the prime receptor of SP, i.e., NK-1R. Pretreatment of mice with the specific NK-1R antagonists CP-96,345 and L-733,060, respectively, 30 min before administration of GalN/LPS, dose dependently reduced plasma transaminase activities, and maximum levels of TNFα and IFNγ (Fig. 2). Both NK-1R antagonists led to significantly reduced plasma transaminase activities at doses \( \geq 5 \) mg/kg. CP-96,345 pretreatment resulted in a significant reduction of plasma levels of both cytokines at 10 mg/kg, whereas a higher dose of L-733,060, i.e., 20 mg/kg, was necessary for same effect. Histological examination of livers from treated and control mice revealed signs of severe inflammatory liver damage in the GalN/LPS-treated group and virtual absence of the inflammatory infiltrate, mainly consisting of granulocytes, as well as reduction of hepatic edema and almost complete absence of hepatocyte apoptosis and necrosis in the L-733,060 pretreated group (Fig. 3). Taken together, NK-1R antagonists exerted effects in the liver comparable to those of permanent depletion of C-fibers by capsaicin.

**Time Course of the Protective Effect of L-733,060 against GalN/LPS-Induced Liver Injury.** To monitor the whole time course of the protective effect of NK-1R blockade in inflammatory liver injury, we pretreated mice with the NK-1R antagonist L-733,060 30 min before GalN and LPS and measured activities of plasma transaminases, as well as plasma levels and intrahepatic mRNA expression of the cy-

![Fig. 1. Protection against GalN/LPS-induced liver injury in mice by capsaicin-induced depletion of primary afferent sensory neurons. Newborn BALB/c mice were pretreated with 100 mg/kg capsaicin s.c. at the 3rd day after birth. Seven weeks later they were challenged with 700 mg/kg GalN i.p. together with 6.5 μg/kg LPS i.p. TNFα was detected 1 h and IFNγ, ALT, and AST 8 h after GalN/LPS administration. Data are expressed as the mean values ± S.E.M.; \( n = 5 \); * \( p \leq 0.05 \) versus capsaicin-nonpretreated control.](http://jpet.aspetjournals.org/article-pdf/10.1124/jpet.117.228107/28083542/16951858/jpet.117.228107.pdf)

![Fig. 2. Protection by the NK-1R antagonists CP-96,345 and L-733,060 against GalN/LPS-induced liver injury in mice. NK-1R antagonists were administered i.p. at the doses indicated 30 min before injection of 700 mg/kg GalN together with 6.5 μg/kg LPS i.p. TNFα was detected 1 h after and IFNγ and ALT 8 h after GalN/LPS administration. Data are expressed as the mean values ± S.E.M.; \( n = 4 \); * \( p \leq 0.05 \) versus saline-treated control; nd, not determined (open bars, CP-96,345-pretreated mice; black bars, L-773,060-pretreated mice).](http://jpet.aspetjournals.org/article-pdf/10.1124/jpet.117.228107/28083542/16951858/jpet.117.228107.pdf)
Cytokines TNFα, IFNγ, IL-6, and IL-10 at several time points following the hepatotoxic challenge. GalN/LPS induced a dramatic increase of plasma ALT and AST activities within 8 h after intervention, which was significantly reduced by the NK-1R antagonist (Fig. 4A). LPS induced the release of cytokines into plasma of GalN-sensitized mice showing differ-
ent kinetics and peak concentrations (Fig. 4B). L-733,060 significantly reduced high plasma levels of TNFα observed at 0.5 and 1 h after GalN/LPS administration. IFNγ levels were reduced only at 8 h after intervention with GalN/LPS. In contrast, the NK-1R antagonist significantly increased the release of the anti-inflammatory and hepatoprotective cytokines IL-10 and IL-6 at the time points of their maximal release. The GalN/LPS-induced time course of cytokine production and the protective effect of L-733,060 were also evident at the intrahepatic mRNA level (Fig. 4, C and D).

**L-7330,060 Affects Transcription Factor Activation in Vivo.** Since SP has been described to activate the transcription factor NF-κB in vitro (Marriott et al., 2000) and since the NK-1R antagonist L-7330,060 differentially affected LPS-induced expression of TNFα and IL-6 in vivo (this study) (i.e., two cytokines carrying a NF-κB binding site in their promoter sequence), we examined the activation of the transcription factors NF-κB and AP-1 in vivo. As shown in Fig. 5, L-7330,060 pretreatment attenuated DNA-binding of NF-κB in GalN/LPS-challenged mice compared with controls receiving saline before GalN/LPS treatment, whereas the antagonist increased DNA-binding of AP-1. DNA binding activity of both transcription factors was determined 1 h after GalN/LPS administration, i.e., close to maximal TNFα and IL-6 production (Fig. 4). Specificity of the DNA-protein complexes was confirmed by incubation of nuclear extracts from GalN/LPS-treated mice, with a 100-fold excess of unlabeled (“cold”) NF-κB, AP-1, or AP-2 binding sequences. Excess of unlabeled specific oligonucleotides (i.e., NF-κB and AP-1, respectively) abolished binding reactions, whereas the AP-2 binding sequence showed no significant influence on binding reactions (data not shown). Hence, LPS-inducible transcription factor activation is affected by blockade of the NK-1R in vivo.

**NK-1 Receptor Expression in the Liver.** To prove the occurrence of the NK-1R in the liver, total RNA was isolated from liver tissue, NPC, lung, and spinal cord and reverse transcribed into cDNA. The NK-1R PCR from liver and NPC cDNA was performed as nested-PCR with primary RT-PCR amplification and a second (nested) PCR reaction in the light cycler system. NK-1R mRNA expression in lung and spinal cord was measured in the light cycler system without previous amplification by RT-PCR. The light cycler PCR products were analyzed on an agarose gel and demonstrated an equal length of the individual fragments in liver, lung, and spinal cord (Fig. 6B). To confirm amplification specificity, PCR products were subjected to a melting curve analysis. The melting

![Fig. 5](image-url) **Activation of NF-κB and AP-1 in livers of GalN/LPS-treated and L-733,060-pretreated mice.** The NK-1R antagonist L-733,060 (20 mg/kg) was administered i.p. 30 min before i.p. injection of 700 mg/kg GalN together with 6.5 μg/kg LPS. One hour after GalN/LPS treatment, nuclear extracts were prepared from liver tissue, as described under Materials and Methods. DNA binding capacity of NF-κB and AP-1 was determined by electrophoretic mobility shift assay. Excess of unlabeled specific oligonucleotides (i.e., NF-κB and AP-1, respectively) abolished binding reactions, whereas the AP-2 binding sequence showed no significant influence on binding reactions (data not shown).

![Fig. 6](image-url) **Detection of an identical NK-1R mRNA fragment in liver, lung, and spinal cord.** Hepatic mRNA was analyzed in the light cycler system for the expression of NK-1R mRNA in comparison to lung and spinal cord (s.c.). In all tissues, identical fragments of NK-1R mRNA were expressed. A, the PCR products of s.c., lung, and liver had the same melting point. B, the PCR products of the light cycler run (A) were transferred to an agarose gel to analyze the fragment size. All PCR products had an identical length of 181 bp (dotted box, liver RT-PCR was performed as nested PCR to enrich the low NK-1R mRNA amount). C, sequencing of the liver PCR product (lane 2) and the s.c. PCR product (bold, lane 1) showed mRNA fragments identical to the NK-1R, GenBank accession no. X62934.
points of the PCR products of NK-1R mRNA were identical in all three tissues tested, i.e., spinal cord, lung, and liver (Fig. 6A). The PCR products of spinal cord and liver were sequenced and found to be identical to GenBank accession no. X62934 (Fig. 6C). NK-1R mRNA was also detectable in NPC and was inducible by pretreatment of mice with LPS 3 or 6 h before isolation of the nonparenchymal liver cell fraction (expression levels, given in x-fold induction: saline treated group, 1.0 ± 0.3; 3-h LPS, 23.1 ± 7.9%; 6-h LPS, 19.4 ± 9.4%; n = 5; *p ≤ 0.05 versus saline control).

NK-1R immunoreactivity was detected in numerous rounded to elongated cells scattered throughout the liver, most likely representing monocytes/macrophages, lymphocytes, and granulocytes (Fig. 7A). Many cells were found in the sinusoids, whereas others were seen in small veins. Immunoreactivity was concentrated on the cell membrane. Granular NK-1R immunoreactivity was also detected in scattered hepatocytes (Fig. 7B). In brain and spinal cord, the pattern of NK-1R immunostaining found in our material was compatible with published data (Fig. 7C). In the liver, no nerve fibers were immunoreactive (Fig. 7, A and B). Negative controls were devoid of immunostaining (Fig. 7D). Taken together, these results clearly demonstrate the presence of the NK-1R in mouse liver where it appeared predominantly in nonparenchymal mononuclear cells but also in hepatocytes.

**Discussion**

In our present study, we have demonstrated that permanent depletion of C-fibers by neonatal treatment of mice with capsaicin and antagonists to the NK-1R, which is the high-affinity receptor for SP, i.e., the prime proinflammatory neuropeptide of C-fibers (Harrison and Geppetti, 2001), protected mice against LPS-induced inflammatory liver injury. Although these nerve fibers are well known to affect peripheral inflammation in skin and joints as well as in gastrointestinal and respiratory tract (Holzer, 1988; Harrison and Geppetti, 2001), only limited information is available on their role in liver inflammation and fibrosis (Casini et al., 1990; Tiegs et al., 1999), and a hepatoprotective effect of NK-1R antagonists has never been demonstrated. The effects of SP and other tachykinins released from the peripheral endings of C-fibers are collectively referred to as "neurogenic inflammation", which has been characterized so far by flare, plasma extravasation, edema formation, and leukocyte infiltration (Holzer, 1988; Harrison and Geppetti, 2001; Severini et al., 2002). Indeed, most of these hallmarks of neurogenic inflammation were histologically also observable in our liver injury model (Fig. 3). Neurogenic inflammation can be elicited by electrical, mechanical, or chemical stimulation of C-fibers (Severini et al., 2002). Chemically, C-fibers can be selectively stimulated by low doses of capsaicin, which has recently been shown to specifically activate vanilloid receptors expressed by these neurons (Caterina et al., 1997). In human skin, the proinflammatory effect of low capsaicin concentrations has been reported to be partially inhibited by glucocorticoids (Tauler et al., 1993). Hence, it seems that the local proinflammatory effector function elicited by capsaicin is mediated by arachidonic acid metabolites and/or cytokines produced by inflammatory cells. Accordingly, the cytokines TNFα and IL-1β have been shown to potentiate capsaicin-induced tracheal neuropeptide release (Hua et al., 1996). Taking into account that neuropeptides such as SP activate monocytes and other immune cells to produce cytokines (Lotz et al., 1988; Rameshwar et al., 1994), this scenario implicates that bidirectional communication between neurons and immune cells elicits a "circulus vitiosus" that finally results in neurogenic inflammation. On the other hand, several immunocytes have been described to synthesize and release tachykinins (extraneuronal source), which may in turn activate immune cells in an autocrine and/or paracrine fashion (Ho et al., 1997; Maggi, 1997). Nevertheless, since both NK-1R antagonization and chemical depletion of C-fibers prevented LPS-induced liver inflammation (this study) and since capsaicin sensitive C-fibers are present in the mouse liver (Tiegs et al., 1999), it seems that the communication between local inflammatory cells, e.g., Kupffer cells, which are the main target cells of LPS in the liver and which seem to express the NK-1R (this study), and nerve terminals of C-fibers is critical for the pathogenic process.

The recent development of selective, nonpeptide NK-1R antagonists has enabled investigation of the physiological and pathophysiological role of SP. Although SP is best known as a pain neurotransmitter, clinical trials reveal that NK-1R antagonists failed to alleviate pain (Rupniak and Kramer, 1999). These antagonists, lacking important side effects (Severini et al., 2002), exhibit potent antidepressant and anti-
emetic efficacy in patients (Rupniak and Kramer, 1999), however. Evidence from experimental animal studies suggest that NK-1R antagonists are powerful drugs for treatment of inflammatory disease in skin, respiratory, and gastrointestinal tract (Harrison and Geppetti, 2001). In these studies, suppression of neurogenic inflammation was measured as attenuation of vasodilation, plasma extravasation, and edema formation, but only limited data are available that correlate these effects with the cytokine response in vivo. In a Salmonella infection model, it has been shown that the SP antagonist spantide II reduced IL-12 and IFNγ mRNA expression (Kincy-Cain and Bost, 1996), and LPS-induced TNFα production in mice was attenuated by the NK-1R antagonist SR 140333 (Dickerson et al., 1998). The latter study did not correlate alterations in TNFα production to LPS-induced pathology, however.

The first high-affinity nonpeptide NK-1 receptor antagonist, CP-96,345, was published by Snider et al. (1991). The in vivo pharmacological activity of CP-96,345 was investigated in the classical bioassay for SP, i.e., stimulation of salivation in the anesthetized rat, that was inhibited by the antagonist at an i.v. dose of 3.4 mg/kg (Snider et al., 1991). In mice (Perretti et al., 1993; Veronesi et al., 1995) or guinea-pigs (Costello et al., 1998; Lin et al., 2001), neurogenic inflammation was attenuated by CP-96,345 at doses of 5 to 15 mg/kg given either i.p., i.v., or s.c. More recently, L-733,060 has been described to inhibit the formalin paw late phase at doses of 0.1 to 10 mg/kg when given intravenously (Rupniak et al., 1996). In our study, both receptor antagonists significantly inhibited liver damage, i.e., release of transaminases, at the same dose range (Fig. 2). Although CP-96,345 significantly inhibited the production of TNFα, the major mediator of GalN/LPS-induced liver injury (Schumann and Tiegs, 1999), at doses of 2.5 to 10 mg/kg i.p., L-733,060 was less effective in suppression of the cytokine response (Fig. 2). This suggests, on the one hand, that L-733,060 has a reduced anti-inflammatory potency compared with CP-96,354 and, on the other hand, that NK-1R antagonists may affect additional pathological pathways in the liver. Indeed, NK-1R antagonists inhibited apoptosis of hepatocytes when liver injury was induced by direct administration of TNFα to GalN-sensitized mice (R. Bang and G. Tiegs, unpublished observations). However, also L-733,060 significantly suppressed expression and release of TNFα and IFNγ at 20 mg/kg i.p. as shown in the time course experiments (Fig. 4).

Accordingly, gene-targeted disruption of the NK-1R was associated with a reduction of the TNFα and IFNγ response in intestinal (Castagliuolo et al., 1998) and chronic liver inflammation (Blum et al., 1999), respectively, and chemical depletion of C-fibers resulted in dramatically reduced release of both cytokines (this study). Since the cytokine inhibitory efficacy of C-fiber depletion was more pronounced compared with that of NK-1R antagonists, it seems that other neuropeptides besides SP are also responsible for this effect. Finally, this study shows for the first time that NK-1R antagonists not only suppress the production of LPS-inducible proinflammatory cytokines, TNFα, and IFNγ but also augment expression and synthesis of the anti-inflammatory and hepatoprotective cytokines IL-10 (Louis et al., 1997) and IL-6 (Mizuhara et al., 1994; Streeetz et al., 2000).

Since antagonization of the NK-1R in vivo differentially regulated LPS-induced expression of two NF-κB and AP-1 dependent cytokines, i.e., TNFα and IL-6 (Dendorfer et al., 1994; Baud and Karin, 2001), respectively, we examined the activation of the transcription factors NF-κB and AP-1. Our results revealed an attenuation of NF-κB and a concomitant increase of AP-1 binding to DNA in livers from L-7330,060 pretreated, GalN/LPS-challenged mice, indicating that the antagonist might have interfered with LPS-inducible transcription factor activation. Provided that these events occurred within the main target cells of LPS in the liver, i.e., the Kupffer cells, our results suggest that the attenuation of NF-κB activation was sufficient to suppress TNFα expression but still allowed transcription of the IL-6 gene and that the increase in AP-1 activation augmented IL-6 expression. This may be explained by different usage of certain regulatory elements in dependence of intracellular signaling, which has been described for regulation of IL-6 gene expression (Dendorfer et al., 1994). An alternative explanation is that NF-κB was down-modulated in Kupffer cells, thereby suppressing TNFα production, whereas AP-1 might have been up-regulated in a different cell population, e.g., in Thelper-2 cells, which are a source of IL-6.

The expression of the NK-1R by human and murine monocytes/macrophages and dendritic cells is well documented (Ho et al., 1997; Marriott and Bost, 2000, 2001); however, NK-1R expression in the liver is only mentioned in one article. Mice chronically infected with Schistosoma mansoni express the receptor on CD4+ granuloma T lymphocytes (Cook et al., 1994). Using a classical RT-PCR technique, the authors failed to identify the receptor in healthy liver tissue. With the help of nested PCR, we were able to identify the receptor also in the normal liver. The identity of the RT-PCR product from liver mRNA with the NK-1R was verified by two means: 1) by showing identical melting points of the RT-PCR products from liver, spinal cord, and lung and 2) by cDNA cloning and sequence analysis proving that the sequence of the receptor in the liver was identical to that in spinal cord (Fig. 5). Moreover, using the same PCR technique, we could identify that the NK-1R in NPC enriched in Kupffer cells, which are the cell population primarily activated by LPS in the liver. Differences in receptor levels of NPC isolated 3 and 6 h after LPS treatment, respectively, suggest induction by cytokines (Marriott and Bost, 2000). Our PCR data were supported by the detection of NK-1R-specific immunofluorescence on mononuclear nonparenchymal cells and hepatocytes in liver sections.

In conclusion, the present and our previous studies (Tiegs et al., 1999) indicate that inflammatory cytokine-mediated liver injury is affected by neuropeptides released from peripheral endings of capsaicin-sensitive nerves. SP seems to be a major player in this scenario, up-regulating the proinflammatory cytokine response by activation of NK-1 receptors, which are also present in the liver. Thus, cytokine-mediated liver diseases might be successfully treated with antagonists to the NK-1R.

Acknowledgments

The NK-1 receptor antagonist CP-96,345 was kindly provided by Dr. H. Berghof (Pfizer GmbH, Karlsruhe, Germany). The perfect technical assistance of Sonja Heinlein, Brigitte Weiss, Andrea Agli, Karin Löschner, and Hedwig Symowskis is gratefully acknowledged.
References


Address correspondence to: Dr. Gisa Teggs, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Fahrstrasse 17, D-91054 Erlangen, Germany. E-Mail: gisa.teggs@pharmakologie.uni-erlangen.de